Trial Profile
The efficacy and safety of low-dose (125mg or 250mg, QD, oral) apatinib in the treatment of advanced Lung Squamous Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer